This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Juno Therapeutics Inc.
Drug Names(s): MUC-16 / IL-12 Armored CAR, CAR-T, JCAR-020
Juno is developing a MUC-16 / IL-12 Armored CAR chimeric antigen receptor T cell (CAR-T) therapy. These cells target MUC-16, the transmembrane protein overexpressed on ovarian and other cancer cells that is cleaved to release circulating CA-125. The Armored CAR technology utilizes transgenic expression of IL-12, an immunostimulatory cytokine that may help these CAR-T cells penetrate the hostile tumor microenvironment.
Juno, Eureka, and Memorial Sloan Kettering
In January 2016, Eureka Therapeutics announced that Memorial Sloan Kettering Cancer Center and Juno Therapeutics have entered into an exclusive license agreement for a novel, fully-human binding domain targeting MUC16 to be used for the potential development and commercialization of chimeric antigen receptor (CAR) cell therapies for patients with MUC16 positive cancers, including ovarian, fallopian tube, and primary peritoneal cancers. The binder was developed under a collaboration agreement between Eureka Therapeutics and Memorial Sloan Kettering Cancer Center.
Under the terms of the exclusive license agreement, Memorial Sloan Kettering granted Juno Therapeutics an exclusive, worldwide license, under both Memorial Sloan Ketterings and Eurekas rights to certain MUC16 binding domains, to develop and commercialize the MUC16 binding domains as part of CAR cell therapies for all indications. In return, Memorial Sloan Kettering...See full deal structure in Biomedtracker
Partners: Eureka Therapeutics, Inc.
Additional information available to subscribers only: